X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RosVivo's RSVI-301 pipeline is the world's first in class new drug candidate that can fundamentally treat diabetes by restoring the function of beta cells that secrete insulin, the cause of diabetes, and at the same time lowering insulin resistance.
Lead Product(s): RSVI-301
Therapeutic Area: Endocrinology Product Name: RSVI-301
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 22, 2022
Details:
RosVivo's new miRNA drug RSVI-301 significantly reduces injection frequency, showed a prolonged effect, and alleviated side effects such as GI dysmotility in animal studies. It is expected that RSVI-301 will become a first-in-class diabetic drug.
Lead Product(s): miRNA Based Therapy
Therapeutic Area: Endocrinology Product Name: RSVI-301
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nexturn Bio
Deal Size: $5.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 30, 2021
Details:
RosVivo recently developed RSVI-301, a new drug pipeline that utilizes miRNA, which is expected to be the next-generation drug, following mRNA, which has attracted attention as a Covid-19 vaccine.
Lead Product(s): miRNA based therapy
Therapeutic Area: Endocrinology Product Name: RSVI-301
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nexturn Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
